Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease

Liver International

Volumn 34, Issue 6, 2014, Pages

  Zelber Sagi, Shira ^a,b   Salomone, Federico ^c   Yeshua, Hanny ^a,d   Lotan, Roni ^a,d   Webb, Muriel ^a   Halpern, Zamir ^a,d   Santo, Erwin ^a,d   Oren, Ran ^a,d   Shibolet, Oren ^a,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c Azienda Sanitaria Provinciale di Catania   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Lipotoxicity; Non alcoholic fatty liver disease; Non high density lipoprotein cholesterol; Population study; Prospective cohort

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; CHOLESTEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIET RESTRICTION; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SERUM; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DYSLIPIDEMIAS; INCIDENCE; ISRAEL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; PROGNOSIS; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; UPREGULATION; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FEMALE; HUMANS; INCIDENCE; ISRAEL; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 84902544448     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12318     Document Type: Article

References (54)

1. Williams CD, Stengel J, Asike MI, et al. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. Gastroenterology 2011; 140: 124-31.
2. Soresi M, Noto D, CEFALù A, et al. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol 2013; 50: 241-49.
3. Farrell GC, Wong VW-S, Chitturi S. NAFLD in Asia[mdash]as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013; 10: 307-18.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
5. Pacifico L, Anania C, Martino F, et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52: 1643-51.
6. Verrijken A, Francque S, Mertens I, et al. Prothrombotic factors in histologically proven NAFLD and NASH. Hepatology 2013; doi: 10.1002/hep.26510. [Epub ahead of print].
7. Vlachopoulos C, Manesis E, Baou K, et al. Increased Arterial Stiffness and Impaired Endothelial Function in Nonalcoholic Fatty Liver Disease: A Pilot Study. Am J Hypertens 2010; 23: 1183-89.
8. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56: 1145-51.
9. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. The American journal of gastroenterology 2011; 106: 460-8; quiz 69.
10. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean Diet Improves Hepatic Steatosis and Insulin Sensitivity in Individuals with Nonalcoholic Fatty Liver Disease. J Hepatol 2013; 59: 138-43.
11. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham heart study. Hepatology 2010; 51: 1979-87.
12. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-91.
13. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
14. Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1098-105.
15. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
16. Farrell GC, Van Rooyen D. Liver cholesterol: is it playing possum in NASH? American Journal of Physiology - Gastrointestinal and Liver Physiology 2012; 303: G9-G11.
17. Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54: 153-9.
18. Defilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013; 227: 429-36.
19. The Emerging Risk Factors C. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
20. Sniderman AD, Williams K, Contois JH, et al. A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes 2011; 4: 337-45.
21. Keinan-Boker L, Noyman N, Chinich A, Green MS, Nitzan-Kaluski D. Overweight and obesity prevalence in Israel: findings of the first national health and nutrition survey (MABAT). Isr Med Assoc J 2005; 7: 219-23.
22. Gore RM. Diffuse liver disease. In: Gore RM, Levine MS, Laufer I, eds. Textbook of Gastrointestinal Radiology, Philadelphia: Saunders, 1994; 1968-2017.
23. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 2007; 46: 700-7.
24. Webb M, Yeshua H, Zelber-Sagi S, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192: 909-14.
25. Mancini M, Prinster A, Annuzzi G, et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1) H magnetic resonance spectroscopy. Metabolism: Clinical and Experimental 2009; 58: 1724-30.
26. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
27. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
28. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-87.
29. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74.
30. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-98.
31. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-403, 403 e1-5.
32. Min H-K, Kapoor A, Fuchs M, et al. Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. Cell Metab 2012; 15: 665-74.
33. Fujita K, Nozaki Y, Wada K, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009; 50: 772-80.
34. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48: 474-86.
35. Matsuzawa N, Takamura T, Kurita S, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46: 1392-403.
36. Savard C, Tartaglione EV, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013; 57: 81-92.
37. Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population. Hepatology 2009; 50: 175-84.
38. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009; 44: 471-7.
39. Enjoji M, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. International journal of hepatology 2012; 2012: 925807.
40. Papandreou D, Karabouta Z, Rousso I. Are dietary cholesterol intake and serum cholesterol levels related to nonalcoholic Fatty liver disease in obese children? Cholesterol 2012; 2012: 572820.
41. Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 2002; 8: 1243-8.
42. Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. Journal of lipids 2011; 2011: 783976.
43. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14(22): 2831-8.
44. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 2004; 101: 11245-50.
45. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. The Lancet 2010; 376: 1916-22.
46. Kimura Y, Hyogo H, Yamagishi S-I, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-57.
47. Hyogo H, Yamagishi S-I, Maeda S, et al. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Digestive and Liver Disease 2012; 44: 492-96.
48. van Rooyen DM, van Gan LT, van Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59: 144-52.
49. Yoneda M, Fujita K, Nozaki Y, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatology Research 2010; 40: 566-73.
50. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-07.
51. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Investig 2002; 110: 905-11.
52. Musso G, Cassader M, Bo S, de Michieli F, Gambino R. Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. Diabetes 2013; 62: 1109-20.
53. Corey KE, Lai M, Gelrud LG, et al. Non-High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2012; 10: 651-56.
54. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.